Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Henry Smith

Interventional Cardiology Greensboro, NC Medical Doctor

NPI 1760582951 CMS profile 171386

1126 N Church St Ste 300, Greensboro, NC 27401

Open in the dashboard

General payments

$3,452

131 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Henry Smith of Greensboro, NC is reported in the CMS Open Payments database as having received $3,452 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $97 2
2023 General $1,049 40
2022 General $846 26
2021 General $382 20
2020 General $279 13
2019 General $799 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Smith
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Henry Smith were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Henry Smith Interventional Cardiology median Middle half National median
2019 $799 $1,097 $329–$3,048 $163
2020 $279 $473 $161–$1,480 $114
2021 $382 $677 $233–$1,827 $132
2022 $846 $978 $333–$2,724 $149
2023 $1,049 $1,136 $382–$2,986 $160
2024 $97 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $411 23 payments
  2. Abbott Laboratories $321 5 payments
  3. Penumbra, Inc. $300 2 payments
  4. Abiomed $299 5 payments
  5. Novartis Pharmaceuticals Corporation $253 16 payments
  6. Medtronic, Inc. $212 5 payments
  7. iRhythm Technologies, Inc. $185 4 payments
  8. Janssen Pharmaceuticals, Inc $153 12 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $151 10 payments
  10. ZOLL Circulation Inc $147 1 payment
  11. Other $1,021 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,452 131 payments
Products named General payments · program years 2019–2024
  1. Repatha $411 23 payments
  2. Impella $299 5 payments
  3. ZIO XT Patch $172 3 payments
  4. Indigo System $160 1 payment
  5. XARELTO $153 12 payments
  6. JARDIANCE $151 10 payments
  7. ONYX FRONTIER $147 2 payments
  8. TherOx DS2 Console $147 1 payment
  9. Downstream Cartridge $147 1 payment
  10. Catheter $147 1 payment
  11. Other $2,094 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,801

Median for Interventional Cardiology: 2,236

Drug cost

$643,938

Median for Interventional Cardiology: $380,412

Branded share of claims

37.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 242 $212,275
Entresto Sacubitril/Valsartan Brand 126 $115,131
Farxiga Dapagliflozin Propanediol Brand 126 $97,750
Repatha Sureclick Evolocumab Brand 96 $80,051
Jardiance Empagliflozin Brand 48 $43,146
Xarelto Rivaroxaban Brand 49 $40,785
Dapagliflozin Dapagliflozin Propanediol Brand 18 $9,556
Vascepa Icosapent Ethyl Brand 15 $7,953
Brilinta Ticagrelor Brand 12 $5,218
Nexlizet Bempedoic Acid/Ezetimibe Brand 11 $4,295

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record